Terapia Ranbaxy, a subsidiary of Ranbaxy Laboratories Ltd, has received market authorisations (MAs) for 20 new products. According to a Ranbaxy press release, the products to be launched in the coming months.

"The list of MAs granted by the National Agency of Medicine refers to products from different therapeutic areas mainly from the cardiovascular, antibiotics or CNS segments," said Dragos Damian, CEO, Terapia Ranbaxy. "These are either new molecules on the market like Citaloran or unique and modern formulations or concentrations like Lamotiran - oral dispersible tablets, Pravator, Quinaran, Terbinaran or Glimeran, among others."

According to Damian these new launches reinforce the company's promise to bring value-added niche products at affordable prices, to the Romanian pharmaceutical market.

With the commercial department structured in business units, Terapia Ranbaxy employs more than 1,200 people, of which 350 form the largest professional field force in the Romanian pharmaceutical market.

According to the latest market analysis, Terapia Ranbaxy is the biggest generics producer in Romania, outperforming all other similar companies active in the market.

In March 2007, Terapia Ranbaxy announced that it had obtained the new manufacturing and import authorization as per EU norms and standards. As a result, the company is entitled to batch test and release products manufactured outside the European Union. With this development, Terapia Ranbaxy becomes the first pharmaceutical company authorized to batch test and release products in Romania.

In June 2006, Ranbaxy Laboratories Ltd. announced the completion of the acquisition process by Ranbaxy Netherlands BV of 96,7 per cent of the top Romanian generics company Terapia SA. The combined operations of Terapia Ranbaxy established the largest Romanian generics company. The commercial name of the company is Terapia Ranbaxy.

In November last year, Terapia Ranbaxy announced the completion of the investment in a new logistic center in Otopeni - Bucharest. The investment' was aimed at increasing the company's warehousing space for all products included in the Terapia Ranbaxy portfolio and for adding bonded customs warehousing services for the products produced by Ranbaxy and imported from India.

The company is undergoing a successful integration process including re-branding, and training of the commercial force and has registered a 50 per cent growth in 2006 in comparison to the previous year.

Established in 1921, Terapia has a strong brand name and a consistent track record of growth and profitability. The company is well placed to benefit from the strong growth Romania will experience in the coming years as healthcare spending moves up to the levels of other Central European countries.